NCT01685242View on ClinicalTrials.gov

A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Allergic Conjunctivitis
Interventions
DRUG

AC-170 0.24%

1 drop in each eye at 2 separate times during a 14 day period

DRUG

AC-170 0%

1 drop in each eye at 2 separate times during a 14 day period

Trial Locations (1)

01810

Andover Eye Associates, Andover

Sponsors
All Listed Sponsors
lead

Aciex Therapeutics, Inc.

INDUSTRY

NCT01685242 - A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle | Biotech Hunter | Biotech Hunter